BTIG Boosts PT on bluebird bio (BLUE) to $83; Sees Favorable FDA Pathway Derisking Pivotal Study Timeline

October 14, 2016 6:21 AM EDT
Get Alerts BLUE Hot Sheet
Price: $66.45 -1.7%

Rating Summary:
    15 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade BLUE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BTIG lifts its price target on Buy-rated bluebird bio (Nasdaq: BLUE) from $72 to $83 following the company's recent R&D day in NYC.

The firm noted the following late Thursday:

  • The design of HGB-207 and HGB-212 should support commercial launch of LentiGlobin for ß0/ß+ genotype and ß0/ß0 genotypes, essentially the entire moderate to severe Beta-thalassemia population, in the US and Europe by 2020.
  • In-line with our preview note (9/13/16), the new manufacturing process for LentiGlobin will allow the company to recapture the ß0/ß0 genotype population (~33% of total moderate to severe Betathalassemia patients) on an accelerated timeline: The company announced the design of HGB-212, which will support use of LentiGlobin to treat the most severe Beta-thalassemia patients ß0/ß0) on an approvable endpoint of transfusion reduction. We think that the combination of the new manufacturing process boosting drug potency along with a transfusion reduction endpoint, versus transfusion independence endpoint, greatly increases odds of clinical success. We forecast US approval by YE2019.
  • European Approval supported by ongoing studies plus interim data from '207 and '212: Management expects that the ongoing HGB-204 and '205 programs will support EU approval for moderate to severe
  • Beta-thalassemia patients with interim support from the new pivotal studies. We forecast EU approval by YE2018.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities


Add Your Comment